Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | GAA | P10253 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | CASP1 | P29466 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10639092 | 0.85 | AKT1 (0.60) | ALDH1A1KDM4EGAAHPGDCASP1 | |
| SCHEMBL6958558 | 0.78 | TLR3 (0.44) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL9635631 | 0.78 | KDM4E (0.54) | ALDH1A1KDM4EGAAHPGDCASP1 | |
| SCHEMBL1168440 | 0.77 | MAPT (0.50) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL6952737 | 0.74 | KDM4E (0.46) | ALDH1A1KDM4EGAAHPGDCASP1 | |
| SCHEMBL6954418 | 0.74 | MAOB (0.56) | ALDH1A1KDM4EGAAHPGDCASP1 | |
| SCHEMBL6948888 | 0.73 | MAPT (0.47) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL9818795 | 0.73 | MAPT (0.61) | ALDH1A1KDM4EGAAHPGDCASP1 | |
| Hydrochloric Acid SCHEMBL6947178 | 0.73 | KDM4E (0.52) | ALDH1A1KDM4EGAAHPGDCASP1 | |
| SCHEMBL6747761 | 0.72 | KMT2A (0.47) | ALDH1A1KDM4EGAAHPGDCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | FISHER MATTHEW J (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0804431-B9 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6448269-B1 | SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-0804431-B1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6020362-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5731324-A | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | SELL, SELPLG, LY96 | ALDH1A1 1693/4885KDM4E 4764/4885GAA 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.